The Akums Drugs and Pharmaceuticals IPO will be open for subscription from July 30, 2024, to August 1, 2024. Through this offering, the company aims to raise approximately ₹1,856.74 crores. This includes a fresh issue of ₹680.00 crores and an offer for sale of up to 17,330,435 equity shares priced at ₹2 each. The IPO allocation is structured with 10% reserved for retail investors, 75% for Qualified Institutional Buyers (QIBs), and 15% for High Net Worth Individuals (HNIs).
Established in 2004, Akums Drugs and Pharmaceuticals has grown into a leading contract development and manufacturing organization (CDMO) both in India and globally. The company is known for its intellectual property rights in various manufacturing processes and offers end-to-end product development and manufacturing solutions. Their services extend to formulation research and development (R&D), regulatory dossier preparation, and testing for both domestic and international markets. Beyond their core CDMO activities, Akums also produces and markets branded pharmaceutical formulations and active pharmaceutical ingredients (APIs).
Recognized as the largest India-focused CDMO by revenue, production capacity, and client base for fiscal year 2023, as per the Frost & Sullivan (F&S Report), Akums manufactures a wide array of dosage forms. These include tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies. In fiscal year 2024, Akums held a 30.2% share of the Indian domestic CDMO market by value, an increase from 26.7% in fiscal year 2021, according to the F&S Report.
Objectives of the Akums Drugs and Pharmaceuticals IPO:
The company intends to allocate the net proceeds from the IPO towards the following purposes:
Repayment or prepayment of the company’s and its subsidiaries’ outstanding debt.
Funding additional working capital needs.
Supporting inorganic growth initiatives through acquisitions.
General corporate purposes.
Akums Drugs and Pharmaceuticals IPO Review:
Review update coming soon.
Akums Drugs and Pharmaceuticals IPO Date & Price Band Details:
| IPO Open: | July 30, 2024 |
| IPO Close: | August 1, 2024 |
| IPO Size: | Approx ₹1856.74 Crores, 27,345,162 Equity Share |
| Fresh Issue: | Approx ₹680.00 Crores, 10,014,727 Equity Share |
| Offer for Sale: | Approx ₹1262.83 Crores, 17,330,435 Equity Share |
| Face Value: | ₹2 Per Equity Share |
| IPO Price Band: | ₹646 to ₹679 Per Share |
| IPO Listing on: | BSE & NSE |
| Retail Quota: | 10% |
| QIB Quota: | 75% |
| NII Quota: | 15% |
| Discount: | N/A |
Akums Drugs and Pharmaceuticals IPO Lot Size:
The minimum lot size for the Akums Drugs and Pharmaceuticals IPO is 22 shares, with an application cost of ₹14,938. Retail investors can apply for a maximum of 13 lots, which equates to 286 shares, amounting to ₹194,194.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 22 | ₹ 14,938 |
| Retail Maximum | 13 | 286 | ₹ 1,94,194 |
| S-HNI Minimum | 14 | 308 | ₹ 2,09,132 |
| B-HNI Minimum | 67 | 1474 | ₹ 10,00,846 |
Akums Drugs and Pharmaceuticals IPO Timeline:
The Akums Drugs and Pharmaceuticals IPO will be open for subscription from July 30 to August 1. Share allotment is set to be finalized on August 2, with the IPO listing anticipated on August 6.
| IPO Open Date: | July 30, 2024 |
| IPO Close Date: | August 1, 2024 |
| Basis of Allotment: | August 2, 2024 |
| Refunds: | August 5, 2024 |
| Credit to Demat Account: | August 5, 2024 |
| IPO Listing Date: | August 6, 2024 |
Akums Drugs and Pharmaceuticals IPO GMP Today:
The current Grey Market Premium (GMP) for the Akums Drugs and Pharmaceuticals IPO stands at ₹155. With a price band of ₹679.00, the estimated listing price is expected to be ₹834, based on the cap price plus today’s GMP. This suggests a potential gain of 22.83% per share.
Akums Drugs and Pharmaceuticals Company Financial Report
| In cr | |||
| Year | Revenue | Expense | PAT |
| 2022 | ₹ 3,694.52 | ₹ 3,874.95 | ₹ 250.87 |
| 2023 | ₹ 3,700.93 | ₹ 3,475.93 | ₹ 97.82 |
| 2024 | ₹ 4,212.21 | ₹ 4,231.45 | ₹ 0.79 |
Akums Drugs and Pharmaceuticals IPO Valuation – FY2024
Review the detailed valuation metrics for the Akums Drugs and Pharmaceuticals IPO, including Earnings Per Share (EPS), Price-to-Earnings (P/E) Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV).
| Earning Per Share (EPS): | ₹-0.28 per Equity Share |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | -0.57% |
| Net Asset Value (NAV): | ₹49.59 per Equity Share |
Peer Group
Divi’s Laboratories
Suven Pharma
Gland Pharma
Torrent Pharma
Alkem Laboratories
Eris Lifesciences
JB Chemicals
Mankind Pharma
Innova Captab
Company Promoters
Sanjeev Jain
Sandeep Jain
Akums Master Trust
Akums Drugs and Pharmaceuticals IPO Registrar
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: Signatureglobal.ipo@linkintime.co.in
Website: https://linkintime.co.in/
Check Akums Drugs and Pharmaceuticals IPO Allotment Status
You can check the allotment status for the Akums Drugs and Pharmaceuticals IPO on the Link Intime website. Click Here
Akums Drugs and Pharmaceuticals IPO Lead Managers (Merchant Bankers)
ICICI Securities Limited
Axis Bank Limited
Citigroup Global Markets India Private Limited
Ambit Private Limited
Company Address
Akums Drugs and Pharmaceuticals Limited
304, Mohan Place,
LSC Saraswati Vihar,
Delhi – 110 034
Phone: +91 11 6904 1000
Email: cs@akums.net
Website: http://www.akums.in/
Akums Drugs and Pharmaceuticals IPO FAQs
What are the dates for the Akums Drugs and Pharmaceuticals IPO?
The IPO will open on July 30, 2024, and close on August 1, 2024. The allotment of shares is expected to be finalized on August 2, 2024, with the shares scheduled to list on August 6, 2024.
What is the price band for the Akums Drugs and Pharmaceuticals IPO?
The price band is set at ₹679.00 per share.
How many shares can retail investors apply for in the Akums Drugs and Pharmaceuticals IPO?
Retail investors can apply for a minimum lot of 22 shares, amounting to ₹14,938. They can apply for up to 13 lots, totaling 286 shares, which amounts to ₹194,194.
What is the purpose of the Akums Drugs and Pharmaceuticals IPO?
The IPO aims to raise approximately ₹1,856.74 crores, including a fresh issue of ₹680.00 crores and an offer for sale of up to 17,330,435 equity shares. The proceeds will be used for debt repayment, capital expenditure, and corporate purposes.
What is the Grey Market Premium (GMP) for the Akums Drugs and Pharmaceuticals IPO?
As of July 25, 2024, the latest GMP is ₹155. Please note that the GMP can fluctuate based on market conditions.
How is the estimated listing price for the Akums Drugs and Pharmaceuticals IPO calculated?
The estimated listing price is derived by adding the GMP to the IPO’s cap price. With a current GMP of ₹155 and a cap price of ₹679.00, the estimated listing price is ₹834.
What are the expected gains or losses per share for the Akums Drugs and Pharmaceuticals IPO?
Based on the current GMP and price band, the expected gain per share is approximately 22.83%.
What are the investor quotas for the Akums Drugs and Pharmaceuticals IPO?
The IPO allocation includes 10% for retail investors, 75% for Qualified Institutional Buyers (QIBs), and 15% for High Net Worth Individuals (HNIs).
